Tesamorelin, liver fat, and NAFLD in the setting of HIV.

Plain Language Summary

Editorial commentary on the landmark tesamorelin NAFLD randomized trial, discussing the significance of demonstrating that a GHRH analog can reduce liver fat and prevent fibrosis progression in HIV-associated NAFLD, contextualizing this finding within the broader NAFLD treatment landscape and the unmet need in HIV. Provides perspective on the tesamorelin NAFLD trial. Establishes the clinical significance of tesamorelin's NAFLD efficacy in HIV—contextualizing the trial results within both HIV metabolic disease management and the broader challenge of treating NAFLD, where tesamorelin represents the first proven pharmacological therapy for a major unmet clinical need.